Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Clarus Funds is a venture capital firm based within Blackstone Life Sciences, focusing on the late-stage development of life sciences products. They collaborate with pharmaceutical, biotech, and medical technology companies to address unmet medical needs. The firm emphasizes funding innovative core products from credible counterparties.
Clarus Funds primarily invests in late-stage life science products and companies, particularly in biotech and healthcare sectors. Their strategy includes funding the development of innovative therapies while aiming for market-unrelated returns at lower risk. They operate across various therapeutic areas, emphasizing collaboration with leading life sciences companies.
Notable investments include **Anthos Therapeutics, Inc.**, which was sold to Novartis in April 2025. In March 2024, they announced a collaboration with Moderna to advance its influenza mRNA vaccine program, providing up to $750 million in funding. Additionally, they led a $2 billion strategic collaboration with **Alnylam Pharmaceuticals** in April 2020, acquiring a royalty interest in inclisiran (Leqvio®).
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.